Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours

Neuropathology and Applied Neurobiology

Volumn 34, Issue 5, 2008, Pages 555-563

  Hayry V ^a   Tynninen, O ^c   Haapasalo, H K ^d   Wolfer J ^e   Paulus, W ^e   Hasselblatt, M ^e   Sariola, H ^a,c   Paetau, A ^c   Sarna, S ^b   Niemela M ^c   Wartiovaara, K ^a   Nupponen, N N ^b,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

BMI 1; Glioma; MDM2; Oligodendroglioma; p16; Prognosis

Indexed keywords

BMI1 PROTEIN; KI 67 ANTIGEN; PARAFFIN; PROTEIN MDM2; PROTEIN P16;

ADULT; ARTICLE; ASTROCYTOMA; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; FINLAND; GERMANY; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STEM CELL; SURVIVAL; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 47749128298     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2008.00949.x     Document Type: Article

References (28)

1. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System. Lyon : IARC Press, 2000
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005 64 : 479 89
3. Stewart LA. Chemotherapy in adult high-grade glioma. A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002 359 : 1011 18
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003 100 : 3983 8
5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004 432 : 396 401
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997 3 : 730 7
7. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003 100 : 15178 83
8. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N E J Med 2006 355 : 1253 61
9. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006 444 : 756 60
10. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006 66 : 6063 71
11. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003 425 : 962 7
12. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003 423 : 302 5
13. Zencak D, Lingbeek M, Kostic C, Tekaya M, Tanger E, Hornfeld D, Jaquet M, Munier FL, Schorderet DF, van Lohuizen M, Arsenijevic Y. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci 2005 25 : 5774 83
14. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005 19 : 1432 7
15. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, Van Lohuizen M, Marino S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004 428 : 337 41
16. Breuer RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, Otte AP, van Kemenade FJ, Postmus PE, Meijer CJ, Raaphorst FM. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 2004 6 : 736 43
17. Breuer RH, Snijders PJ, Sutedja GT, Sewalt RG, Otte AP, Postmus PE, Meijer CJ, Raaphorst FM, Smit EF. Expression of the p16 (INK4a) gene product, methylation of the p16 (INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 2005 48 : 299 306
18. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005 115 : 1503 21
19. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006 66 : 6225 32
20. Tynninen O, Aronen HJ, Ruhala M, Paetau A, Von Boguslawski K, Salonen O, Jaaskelainen J, Paavonen T. MRI enhancement and microvascular density in gliomas. correlation with tumor cell proliferation. Invest Radiol 1999 34 : 427 34
21. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000 18 : 636 45
22. Kirla R, Salminen E, Huhtala S, Nuutinen J, Talve L, Haapasalo H, Kalimo H. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and ki-67 labelling in high grade astrocytomas treated with radiotherapy. J Neurooncol 2000 46 : 71 80
23. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H, Kalimo H, Paljarvi L, Isola J, Haapasalo H. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol 1999 41 : 205 11
24. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001 2 : 731 7
25. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, van Tellingen O, van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007 12 : 328 41
26. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005 25 : 1 7
27. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, Center A, Heiss J, Rosenblum M, Mikkelsen T, Zenklusen JC, Fine HA. High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res 2006 66 : 9428 36
28. Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 2006 25 : 4370 5